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Abstract: Phosphoramidate pro-nucleotides (ProTides) have revolutionized the field of anti-viral
and anti-cancer nucleoside therapy, overcoming the major limitations of nucleoside therapies and
achieving clinical and commercial success. Despite the translation of ProTide technology into the
clinic, there remain unresolved in vivo pharmacokinetic and pharmacodynamic questions. Positron
Emission Tomography (PET) imaging using [18F]-labelled model ProTides could directly address key
mechanistic questions and predict response to ProTide therapy. Here we report the first radiochemical
synthesis of [18F]ProTides as novel probes for PET imaging. As a proof of concept, two chemically
distinct radiolabelled ProTides have been synthesized as models of 3′- and 2′-fluorinated ProTides
following different radiosynthetic approaches. The 3′-[18F]FLT ProTide was obtained via a late
stage [18F]fluorination in radiochemical yields (RCY) of 15–30% (n = 5, decay-corrected from end of
bombardment (EoB)), with high radiochemical purities (97%) and molar activities of 56 GBq/µmol (total
synthesis time of 130 min.). The 2′-[18F]FIAU ProTide was obtained via an early stage [18F]fluorination
approach with an RCY of 1–5% (n = 7, decay-corrected from EoB), with high radiochemical purities
(98%) and molar activities of 53 GBq/µmol (total synthesis time of 240 min).
Keywords: fluorination; ProTides; fluorine-18; radiolabelling; PET imaging
1. Introduction
Clinically approved nucleoside analogues occupy a unique place in drug therapy due to their
ability to interfere in biosynthetic and metabolic pathways fundamental to aberrant cellular replication
and growth. This is particularly apparent in conditions such as cancer [1] and viral infections [2],
where nucleoside analogues are able to inhibit essential human or viral enzymes such as thymidylate
synthase or ribonucleotide reductase.
Despite their well-established value in drug therapy, nucleosides suffer from a number of
drawbacks as therapeutic agents. Cellular entry of nucleosides through the outer cell membrane requires
the active participation of concentrative and equilibrative nucleoside transporters; down-regulation of
transporters in cancer cells for example constitutes a known drug resistance mechanism [3]. Following
cellular uptake, nucleosides require activation via (normally) three successive enzyme-mediated
phosphorylation steps (Figure S1) [4]. The first kinase-mediated phosphorylation is most frequently
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the rate-limiting step prior to incorporation of the active therapeutic nucleotide tri-phosphate within
targets such as DNA/RNA. The requirements for transporter-mediated cellular entry and subsequent
phosphorylation to the active form limit the therapeutic efficacy of nucleoside analogues. For example,
the anticancer drug gemcitabine, widely used in pancreatic, non-small cell lung, ovarian and breast
cancer therapy, is associated with levels of patient response as low as 20% [5].
Given the well-established drawbacks associated with nucleoside analogues, a great deal of
research effort has been devoted towards the development of pro-nucleotides [6]. These nucleotide
derivatives are defined as analogues able to by-pass the requirement for nucleoside membrane
transporters and deliver a masked monophosphate that subsequently breaks down to a nucleotide
monophosphate, or nucleotide derivative, within the cell. The most successful approach to this problem
has been the phosphoramidate pro-nucleotides (ProTides) pioneered by McGuigan and colleagues
at Cardiff University, U.K. [6]. The ProTide approach has revolutionized the field, delivering greatly
enhanced concentrations of active nucleotide triphosphate within the diseased cell and improving
clinical efficacy in important areas of anticancer and antiviral therapy. Examples of success in the
antiviral field include the hepatitis C drug sofosbuvir (Gilead Sciences, Inc., Foster City, CA, USA),
launched in 2014 to radically address the high level of unmet medical need in this common disease
and achieving the status of the world’s top-selling drug worldwide following launch [7]. Within the
anticancer field, several agents have progressed to clinical evaluation with very promising early clinical
data. These include the gemcitabine ProTide NUC-1031 (Acelarin), discovered and developed through
a collaboration between Cardiff University and NuCana plc. Acelarin is currently in Phase III clinical
evaluation in pancreatic cancer [8].
Despite the emerging clear clinical advantages of the ProTide approach, evidence at the molecular
level for the accumulation of ProTides at the in vivo site of action is currently lacking. A potential
solution to this problem would be to label ProTides such that they were amenable to non-invasive
molecular imaging in vivo. In this regard, Positron Emission Tomography (PET) represents an attractive
solution. PET imaging is a sensitive and rapidly emerging molecular imaging technology, widely used
in prognostic and diagnostic clinical applications [9]. The basis of PET imaging is the incorporation of a
radioactive PET-emitting nuclide into the biomarker or drug molecule of interest. The positron released
then annihilates close to the site of emission by electron collision, generating two γ-rays (511 Kev) that
are detected by coincidence measurement followed by 3D image reconstruction. This annihilation
event locates the site of origin of the target molecule with a high level of sensitivity [10]. The choice of
PET isotope is crucial; amongst the many options available 18F has emerged as the non-metal nuclide of
choice due to its intermediate half-life (110 min), relatively low positron energy and exclusive positron
mode of decay [11].
The incorporation of 18F into small molecules provides significant challenges for the radiochemistry
community. The routinely utilized 18F-fluoride (dried and purified from aqueous fluoride solution
from the cyclotron nuclear reactor source) is poorly nucleophilic, and electrophilic options derived from
fluorine gas are disfavoured [12]. In addition, the half-life of 18F (110 min) means that 18F-incorporation
normally has to occur at a late stage of multi-step syntheses, where purification, QC and formulation
for patient administration is necessary within a few hours to generate a significant PET signal. These
challenges are not insurmountable, and a range of 18F-labelled biomarkers and drugs have been
produced and applied in clinical medicine. This is best exemplified by the routine use of the gold
standard PET biomarker [18F]FDG (fluorodeoxyglucose) in cancer diagnosis, staging and monitoring
of response to therapy [13].
Building on our previous experience of 18F-radiolabelling of nucleosides for PET imaging [14,15],
we set out to apply our technology to the ProTide field. Here we report the first radiosynthetic routes to
both 3′- and 2′-fluorinated model ProTides. Application of this technology could help to improve both
diagnostic and prognostic applications of ProTide technology in the clinic, with profound implications
for this exciting area of anticancer and antiviral therapy.
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2. Results and Discussion
As a proof of concept, two [18F]-radiolabelled ProTides have been synthesised. The [18F]FLuoro
Thymidine (FLT) ProTide (1) and the [18F]Fluoro-Iodo-ArabinofuranosylUracil (FIAU) ProTide (2)
(Figure 1) were our chosen model standards for 3′-fluorinated and 2′-fluorinated ProTides, respectively.
Figure 1. Structures of the [18F]FLuoroThymidine (FLT) ProTide (1) and [18F]Fluoro-Iodo-
ArabinofuranosylUracil (FIAU) (ProTide (2).
2.1. [18F]FLT- a Prototypical 3′-fluorinated ProTide
[18F]FLT, a 3′-fluorinated nucleoside, is an established PET imaging agent used as a tumour
proliferation biomarker [16]. Synthetic approaches involving a late stage [18F]-fluorination of different
precursor molecules of [18F]FLT have been extensively studied [15]. Moreover, our group has previously
reported the synthesis of a series of (non-radiolabelled) FLT ProTides that showed a relatively safe
toxicological profile compared to the parent nucleoside as well as moderate anti-HIV activity [17].
For these reasons, [18F]FLT ProTide has been selected as a target compound in this study to represent the
class of 3′-fluorinated ProTides. The choice of the phenol group as aromatic moiety and the L-alanine
ethyl ester as the amino acid ester on the phosphoramidate moiety were dictated by the accessibility of
the starting materials as well as the favourable yields associated with the coupling reactions involved
in the synthesis [17]. The radiochemical synthesis of [18F]FLT ProTide (1) was planned accordingly
taking into account the short half-life of fluorine-18 (110 min), with the [18F]fluorination occurring at
a late stage in the synthesis (Scheme 1). The challenge for this radiosynthetic plan was therefore to
identify a precursor molecule with a balanced reactivity towards the weakly nucleophilic [18F]fluoride
with stability in the harsh thermal conditions used for the radiolabelling step. A series of good leaving
groups {methanesulfonyl (mesyl); p-toluenesulfonyl (tosyl); p-nitrophenylsulfonyl (nosyl)} for the key
nucleophilic fluoride displacement reaction (intermediates 4–7) were selected for reaction optimization.
Scheme 1. Late stage fluorination approach for the synthesis of the [18F]FLT ProTide (1).
2.1.1. Synthesis of the Cold FLT ProTide Standard
A cold non-radioactive standard of the [18F]FLT ProTide was synthesized according to established
ProTide chemistry protocols (Scheme 2) [18]. The phosphorochloridate intermediate (10) was
first obtained from the L-alanine ethyl ester hydrochloride salt and the commercially available
dichlorophosphate (9) using triethylamine as base. Compound 10 was obtained as a mixture of
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diastereoisomers because of the formation of a new stereocenter at the phosphorus atom in a 1:1 Rp: Sp
ratio. Commercially available FLT (8; Carbosynth) was then reacted with the phosphorylating reagent
using tert-butyl magnesium chloride (t-BuMgCl) as a hindered base. The desired product (11) was
obtained as a mixture of diastereoisomers (1:1 Rp:Sp) with a yield of 24% and was used as standard
analytical control for studies of the radiochemical synthesis of [18F]FLT ProTide.
Scheme 2. Synthesis of the cold standard FLT ProTide. Reagents and conditions: (a) l-alanine ethyl
ester hydrochloride salt, Et3N, −78 ◦C to rt, anh. CH2Cl2, 3 h, 92%; (b) t-BuMgCl, anh. THF, 18 h, 24%.
Stability studies were performed on the non-radioactive standard to test the susceptibility of the
ProTide phosphoramidate to the high temperatures used during the [18F]fluorination. The dynamic
behaviour of the phosphoramide moiety was therefore monitored at temperatures ranging from 50 ◦C to
120 ◦C. 31P NMR spectroscopy is particularly well suited for this purpose considering the characteristic
chemical shifts at around δ 4 ppm of the phosphoramidate backbone of the FLT ProTide [17]. The two
31P NMR peaks of the diasteroisomeric mixture were observed to be stable when the compound
was heated up to 120 ◦C, confirming its stability to the high temperatures that were used during the
radiolabelling step (see Supplementary Materials, Figure S2).
2.1.2. Synthesis of a Series of Organophosphates as Precursor Molecules of the [18F]FLT ProTide
To design a late stage fluorination for the class of 3′-substituted ProTides, a multi-step synthesis
was performed to obtain a thymidine based ProTide with an anhydroxylic group in the 3′-β position of
the ribose ring. The first step consisted of the formation of the 3′-β hydroxy intermediate (13) via a
Mitzunobu reaction [18] followed by hydrolysis of the intermediate compound 12 to obtain inversion
of the stereochemistry of the hydroxylic group at the 3′ position of the thymidine. The intermediate 14
was again synthesised following the standard procedure previously described. N-methylimidazole
(NMI) was used at this time as the coupling reagent because of the presence of the free hydroxylic
group in the 3′-position that could compete with the 5′-OH group for the phosphorylation [19].
The hydroxyl group at the 3′-β position of 14 is a poor leaving group for the nucleophilic
substitution reaction with anhydrous [18F]fluoride. Therefore, the 3′-hydroxyl group was selectively
activated with a series of sulfonic esters to produce good leaving groups (4–6) for reaction with the
weakly nucleophilic [18F]fluoride, in accordance with literature precedent [11,20]. The intermediate
14 was reacted with mesyl chloride, tosyl chloride and nosyl chloride respectively in presence of a
weak base such as pyridine or Et3N with or without AgOTf as a catalyst (Scheme 3). To improve
the stability of precursor 6 and avoid competitive cyclization/elimination reaction upon reaction
with the fluorine-18 [21], protection of the NH group of the pyrimidine ring was performed with
the tert-butoxycarbonyl group (Boc). Surprisingly, the major product of the reaction observed
was the di-protected ProTide (7) bearing Boc groups at both the NH of the pyrimidine ring and
the phosphoramidate moiety. The abundance of the di-Boc protected compound compared to
the mono-protected product as result of the Boc-protection reaction, together with the need for a
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stable fluorination precursor, led us to choose the di-Boc protected product (7) for the following
radio-fluorination step.
Scheme 3. Synthetic procedure for the mesyl, tosyl and nosyl precursors. Reagents and conditions:
(a) PPh3, DIAD, anh. CH3CN, −20 ◦C to 0 ◦C, 5 h, 52%; (b) l-alanine ethyl ester hydrochloride salt, Et3N,
−78 ◦C to rt, anh. CH2Cl2, 3 h, 92%; (c) NaOH (1.5 M), CH3OH, 90 ◦C, 3 h, 64%; (d) Phosphorochloridate,
NMI, anh. THF, 25 ◦C, 18 h, nitrogen atm, 18.4%; (e) Mesyl chloride, Et3N, anh. CH2Cl2, nitrogen atm.,
0 ◦C to 25 ◦C, 1.5 h, 29.5%; (f) Tosyl chloride, pyridine, AgOTf, 0 ◦C to rt, 2 h, 35%; (g) Nosyl chloride,
pyridine, AgOTf, 0 ◦C to rt, 2 h, 60%; (h) Di-tert-butyldicarbonate, pyridine, rt, 16 h, 56%.
2.1.3. Radiochemical Synthesis of the [18F]FLT ProTide
The Eckert & Ziegler modular lab was used for the [18F]-fluorination following the schematic
described in the Supplementary Material (Figure S3). K [18F]F/K222/K2CO3 was used as the fluorinating
agent and a series of solvents and temperatures were tested to establish the best conditions for
the radio-fluorination. The methanesulfonyl (mesyl) precursor (4) and the p-toluenesulfonyl (tosyl)
precursor (5) did not give the expected [18F]-radiolabelled compound as observed from the radio
HPLC chromatograms (Figures S4 and S5 and Tables S1 and S2). The p-nitrobenzenesulfonate (nosyl)
precursor 6 was, as expected, the most reactive among the three organosulfonate leaving groups for
the SN2 reaction with the weak nucleophile [18F]fluoride [11], but lacked stability with the formation
of multiple radiolabeled polar compounds and a radiochemical yield < 1% as determined by analytical
HPLC (Figure S6 and Table S3).
To increase the stability of the precursor, two Boc protecting groups were added, as previously
described, leading to the formation of compound 7. This precursor proved to be the best substrate
for [18F]-fluorination. Radio-HPLC showed a major product (15) with a retention time at around
15 min (Figure S7). This suggested that the desired Boc radiolabelled product was formed therefore
supporting the hypothesis that the Boc double protection provides improved stability for the nosyl
precursor. The deprotection step was then carried out by adding 2 N HCl for 10 min at 95 ◦C [22] and
the final compound was then neutralised with a 2 M NaOH solution. Gratifyingly the major product
of this reaction was the [18F]FLT ProTide (1) with few other minor by-products (Scheme 4, Figure S8).
Scheme 4. 18F-fluorination of the Boc protected nosyl derivative 7 and deprotection. Reagents and
conditions: (a) 18F−, Kryptofix, anh. CH3CN, 90 ◦C, 30 min.; (b) 2 N HCl, 95 ◦C, 10 min.
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The compound was then purified by semi-preparative HPLC (Phenomenex Synergi 4µ Hydro-RP
80, C-18, 10 × 250 mm) and was eluted after 35 min at a flow rate of 3.5 mL/min using 30% CH3CN/70%
H2O as the mobile phase. To confirm the identity of the 18F-product (1), an aliquot of the purified sample
was analysed by HPLC (Phenomenex Synergi 4µ Hydro-RP 80, C-18, 4.6 × 250 mm) via co-elution with
the cold standard. The 18F-product showed a Rt of 9.5 min and the cold standard co-injected eluted at
a Rt of 9.2 min (Figure 2) confirming the identity of the [18F]FLT ProTide (1). Radiochemical reactions
were carried out using starting activities between 1.5–8 GBq, leading to final product activities of
300–580 MBq in a good radiochemical yield (RCY) of 15–30% (n = 5, decay-corrected from end of
bombardment (EoB)). High radiochemical purities (≥97%) and molar activities of 56 GBq/µmol were
obtained, and the total synthesis time was 130 min after the end of bombardment (EoB).
Figure 2. HPLC of the [18F]FLT ProTide (1). (a) Radioactive chromatogram of the purified [18F]FLT
ProTide with Rt of 9.5 min; (b) UV chromatogram of the reaction mixture co-spiked with the cold
standard (Rt: 9.2 min). HPLC system: 90% H2O/10% CH3CN, to 50% H2O/50% CH3CN.
2.2. [18F]FIAU - A Prototypical 2′-Fluorinated ProTide
2′-deoxy-2′-[18F]fluoro-1-β-D-arabinofuranosyl-5-iodouracil ([18F]FIAU), is a PET biomarker used
for imaging HSV1-tk gene expression in biological processes including transcriptional regulation,
lymphocyte migration and stem-cell tracking [23]. Building on previous developed radiosyntheses
of this tracer for PET imaging, we decided to synthesise a ProTide of [18F]FIAU (2) as a model of the
class of the 2′-fluorinated ProTides [10] introducing 18F early in the synthetic sequence as outlined in
Scheme 5.
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Scheme 5. Synthetic approach for the radiosynthesis of the [18F]FIAU ProTide (2).
2.2.1. Synthesis of the Non-Radioactive FIAU ProTide Standard
A cold standard of FIAU ProTide (21) was synthesised following the synthesis outlined in Scheme 6.
The commercially available compound 18 was firstly iodinated at the C-5 position upon reaction with
iodine and cerium ammonium nitrate to give compound 19 under previously reported conditions [24].
The ProTide 21 was synthesised using methodology described above with the exception that the
L-alanine ethyl ester was here replaced by a benzyl ester (using compound 20). The phosphoramidate
21 was obtained as a diasteroisomeric mixture for co-injection with the radiolabelled counterpart, the
[18F]FIAU ProTide, to confirm its identity by HPLC.
Scheme 6. Synthesis of the non-radioactive standard FIAU ProTide (21). Reagents and conditions: (a)
I2, Ceric ammonium nitrate, ACN, 75 ◦C, 1 h, 60%; (b) l-alanine benzyl ester hydrochloride salt, Et3N,
−75 ◦C to rt, anh. CH2Cl2, 3 h, 88%; (c) NMI, anh. THF, 0 ◦C to rt, 16 h, 10%.
2.2.2. Radiochemical Synthesis of the [18F]FIAU ProTide
The first step consisted of the radioactive fluorination of the commercially available sugar 16
bearing a triflate as leaving group according to literature precedent ([18F]fluoride, Kryptofix, anh.
CH3CN, 95 ◦C) [25]. The reaction was again carried out using the E&Z modular lab. After purification
with an alumina sep-pak [26], the radiolabelled sugar (17) was used for the next step without further
purification. When an aliquot of the radioactive mixture was co-spiked with a cold standard (Sigma
Aldrich), it showed the same retention time at around 3 min (Figure S10).
The second step consisted in the protection of the base moiety 22 with hexamethyldisilazane and
the catalyst trimethylsilyl trifluoromethanesulfonate (TMSOTf) [27] to obtain compound 23 that was
coupled with the radiolabelled sugar (17) without further purification. The glycosylation reaction led
to the formation of two anomers following removal of the TMS groups under basic conditions, the
β-anomer ([18F]FIAU) (24) and the α-anomer in a ratio 2:1 (Figure S10). Attempts to increase the speed
of the reaction by either reducing the time or using a combination of catalysts (TMSOTf and SnCl4)
led to incomplete conversion into the final product or favoured the formation of the α-anomer (ratio
β:α = 1:1.3), as shown in Table 1 [27,28]. Therefore, based on these attempts to optimise the reaction
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conditions, the synthetic pathway in Scheme 7 was established as the most suitable for synthesis of
[18F]FIAU 24.
Table 1. Tentative optimization of the glycosylation reaction.
Solvent Temperature Time Catalyst Ratio β:α
CH3CN 85 ◦C 30 min TMSOTf Incomplete
CH3CN 85 ◦C 45 min TMSOTf Incomplete
CH3CN 85 ◦C 1 h TMSOTf 2:1
CH3CN 95 ◦C 30 min TMSOTf Incomplete
CH3CN 85 ◦C 15 min TMSOTf+SnCl4 [24] 1:1.3
Scheme 7. Radiochemical synthesis of [18F]FIAU (24). Reagents and conditions: (a) 18F-, Kryptofix,
anh. CH3CN, 95 ◦C, 30 min; (b) Hexamethyldisilazane, TMSOTf, anh. dichloroethane, 85 ◦C, 2 h;
(c) anh. CH3CN, 85 ◦C, 1 h; (d) NaOCH3/CH3OH, 85 ◦C, 10 min.
Finally the last step consisted of the coupling between the [18F]FIAU (24) and the appropriate
phosphorochloridate previously synthesised according to the standard NMI promoted procedure [19].
The phosphoramidate reaction between phosphorochloridate and nucleoside under non-radioactive
conditions is reported in the literature as a room temperature reaction over 16h [19]. However, this
procedure would not be suitable for a reaction as time sensitive as one involving the short-lived
radionuclide fluorine-18 (t1/2 = 109.7 min.). For this reason, we developed an assay to observe the
progress of the phosphoramidate bond formation. The substrate of this assay was the non-radioactive
FIAU and the reaction was monitored via 31P NMR spectroscopy and HPLC chromatography.
Surprisingly we observed almost complete conversion into the ProTide after 15 min when the reaction
was conducted at mild temperatures (50 ◦C) to then reach a steady state at around 30 min (Figure 3).
Figure 3. Conversion rate of FIAU (19) into FIAU ProTide (21): % conversion to FIAU ProTide during
the coupling reaction was calculated over time at 50 ◦C using 31P NMR spectroscopy and analytical
HPLC chromatography.
We therefore applied the same conditions for the radioactive reaction and observed formation of
the final compound (2) at 50 ◦C after 15–20 min. (Scheme 8).
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Scheme 8. Synthesis of the [18F]FIAU ProTide. Reagents and conditions: (a) NMI, anh. THF, 50 ◦C,
20 min.
Satisfyingly, when an aliquot was taken to perform an analytical HPLC evaluation, [18F]FIAU
ProTide (2) was observed to be the main product of the reaction (Figure S11). The product was then
isolated via semi preparative HPLC and was eluted after 23 min at a flow rate of 3.5 mL/min using 50%
CH3CN/50% H2O as the mobile phase. An aliquot of the purified sample was analysed by analytical
HPLC via co-elution with the non-radioactive standard (Figure 4).
Figure 4. HPLC of [18F]FIAU ProTide. (a) Radioactive chromatogram of the purified [18F]FIAU ProTide
with Rt of 12.3 min; (b) UV chromatogram of the [18F]FIAU ProTide co-spiked with the non-radioactive
standard. (Rt of non-radioactive standard: 12.2 min). HPLC system: 90% H2O/10% CH3CN to 50%
H2O/50% CH3CN.
Radiochemical reactions were carried out using starting activities between 7–15 GBq, leading to
final product activities of 8–46 MBq in RCY of 1–5% (n = 7, decay-corrected from end of bombardment
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(EoB)), with high radiochemical purities (98%) and molar activities of 53 GBq/µmol. The total synthesis
time was 240 min after the end of bombardment (EoB), within the acceptable range of just over two
half-lives for future pre-clinical/clinical applications.
3. Materials and Methods
3.1. General Non-Radioactive Chemistry: Reagents and Analytical Methods
All the reagents and anhydrous solvents were purchased from Sigma-Aldrich. FLT was purchased
from Carbosynth Ltd. (Berkshire, UK). Fluka silica gel (35–70 mm) was used as stationary phase
for column chromatography. 1H NMR spectra were acquired for all known compounds whereas for
novel compounds 1H NMR, 31P NMR, 13C NMR, MS and HPLC data were acquired. 1H NMR were
measured using a Bruker Advance Ultra Shield spectrometer (500 MHz) at ambient temperature. Data
were recorded as follows: chemical shift in δ ppm from internal standard tetramethylsilane; multiplicity
(s = singlet; d = doublet; t = triplet; m = multiplet); coupling constant (Hz); integration and assignment.
13C NMR spectra were measured using a Bruker Advance Ultra Shield spectrometer (125 MHz) at
ambient temperature. Chemical shifts were recorded in ppm from the solvent resonance used as the
internal standard (e.g., CDCl3 at 77.00 ppm). 31P NMR spectra were recorded on a Bruker Advance
Ultra Shield spectrometer (202 MHz) at ambient temperature. 19F NMR spectra were recorded on a
Bruker Advance Ultra Shield (474 MHz) spectrometer at ambient temperature. High-performance
liquid chromatography (HPLC) analysis was conducted on an Agilent Technology 1200 Series System
at the PET imaging centre in Cardiff (PETIC) with an analytical reversed phase column (Phenomenex
Synergi 4µ Hydro-RP 80, C-18, 4.6 × 250 mm). Thin-layer chromatography (TLC) was conducted
on pre-coated silica gel 60 GF254 plates. Mass spectrometry analysis (LC-ESI-MS) was performed on
a Bruker micro-TOF and with an Agilent 6430 T-Quadrupole spectrometer. High-resolution mass
spectrometry (ESI-HRMS) was determined at the EPSRC National Mass Spectrometry facility at
Swansea University (Swansea, UK).
3.2. General Radiochemistry: Source, Equipment and Analytical Methods
[18F]Fluoride was produced in an IBA Cyclon 18/9 cyclotron using the 18O(p,n)18F nuclear
reaction. 18O-Enriched water (enrichment grade 98%, 2.2 mL, Nukem GmbH, Alzenau, Germany)
was irradiated with 18 MeV protons. Radiofluorinations were performed on an Eckert & Ziegler
module system. The drying procedures were performed with a vacuum pump N820 (Neuberger,
Freiburg, Germany). Semi-prep HPLC (Phenomenex Synergi 4µ Hydro-RP 80, C-18, 10 × 250 mm)
with a smartline pump 100–126 connected to the Eckert & Ziegler module system was used for the
purification of the radiolabelled products. QMA and Al sep-pak (Waters corp., Milford, MA, USA)
were used for purification of fluorine-18 intermediates. HPLC analytical evaluation was conducted on
an Agilent Technology 1200 Series System with an analytical reversed phase column (Phenomenex
Synergi 4µ Hydro-RP 80, C-18, 4.6 × 250 mm) coupled with a RAM/RAM Model 4 detector (Lablogic
System, Ltd., Sheffield, UK) for radio-HPLC purposes.
3.3. Procedures and Spectroscopic Data for the Synthesis of the [18F]FLT-ProTide
Synthesis of (2S)-ethyl-2-((chloro(phenyl)phosphoryl)amino)propanoate (10). C11H15ClNO4P; MW: 291.6.
Compound 10 was synthesized according to standard procedure [19]. Anhydrous triethylamine (2 eq;
0.662 mL; 0.480 g; 4.74 mmol) was added to the phenyldichlorophosphate (9) (1 eq; 0.354 mL; 0.500 g;
2.37 mmol) and l-alanine ethyl ester hydrochloride salt (1 eq; 0.364 g; 2.37 mmol) in anhydrous CH2Cl2
(5 mL) to obtain the final product 10 as a yellowish oil that was used without further purification. Yield:
92%. 1H NMR (500 MHz, CDCl3): δ 7.35–7.41 (m, 2H, Ar-H), 7.21–7.30 (m, 3H, Ar-H), 4.53 (m, 1H,
NH), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 1.51 (m, 3H, CH3), 1.23 (m, 3H, CH3). 31P NMR (202 MHz,
CDCl3): δ 7.71, 8.05. Spectroscopic data in agreement with literature [29–31].
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Synthesis of (2S)-ethyl2-(((((2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (11). C21H27FN3O8P, MW: 499.4.
FLT (8) (1 eq; 0.100 g; 0.41 mmol) in anhydrous THF, was reacted with tBuMgCl (1.5 eq; 0.08 mL)
under nitrogen atmosphere. The reaction mixture was stirred at rt for 30 min. A solution of the
phosphorochloridate 10 (2 eq; 0.239 g; 0.82 mmol) in anhydrous THF was then added dropwise and
the reaction mixture was left to stir overnight. The solvent was then evaporated under reduced
pressure and the residue was purified by silica gel column chromatography (CH2Cl2/CH3OH from
100% CH2Cl2 to 95% CH2Cl2) to give the FLT ProTide (11) as a yellowish oil. Yield: 23.5%. Rf: 0.44
in 90% CH2Cl2/10% CH3OH TLC system. 1H NMR (500 MHz, CDCl3): δ 8.60 (br s, 1H, NH), 7.55
(s, 1H, H-6), 7.33–7.41 (m, 2H, Ar-H), 7.20–7.29 (m, 3H, Ar-H), 6.23–6.30 (m, 1H, H-1′), 5.33 (m, 1H,
H-3′), 4.43–4.53 (m, 2H, NH, H-4′), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 3.35-3.51 (m, 2H, H-5′, H-5”),
2.48–2.51 (m, 1H, H-2”), 2.55–2.33 (m, 1H, H-2′), 1.93–1.74 (m, 3H, CH3, thy), 1.30–1.18 (d, J = 6.9,
CH3-ala). 19F NMR (479 MHz, CDCl3): δ −173.70, −175.20. 31P NMR (202 MHz, CDCl3): δ 4.34, 4.12.
MS (ESI+): 498.1 [M − H+]. HPLC: Rt: 10.8 min; Purity > 96%; [Gradient: (0′) 95%H2O/5% CH3CN −
(5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN]. Spectroscopic
data in agreement with literature [17].
Synthesis of (3R,5R)-3-(hydroxymethyl)-8-methyl-2,3-dihydro-5H,9H-2,5-methanopyrimido[2,1-b][1,5,3]
dioxazepin-9-one (12). MF: C10H12N2O4; MW: 224.22. Thymidine (3) (1 eq, 0.250g, 1.32mmol) and
triphenylphosphine (Ph3P) (2 eq, 0.541 g, 2.64 mmol) were suspended in anhydrous acetonitrile
(20 mL) and cooled down to −15 ◦C. Diisopropylazadicarboxylate (DIAD) (2 eq, 0.406 mL, 0.417 g,
2.64 mmol) was then added dropwise maintaining the temperature below −5 ◦C with vigorous stirring.
The reaction was allowed to stir for 5h at 0 ◦C and then again cooled down to −20 ◦C. Cold ethyl acetate
(20 mL) was added and the reaction was stirred for a further 15 min. A white precipitate was formed
and was collected by Buchner filtration. The filtrate was washed with cold ethyl acetate and evaporated
to dryness. The resulting crude compound was purified by silica gel column chromatography using
90% CH2Cl2/10% CH3OH as eluent to obtain the product 12 as a white solid. Yield: 52%. Rf: 0.5. 1H
NMR (500 MHz, DMSO-d6): δ 7.55 (d, J = 1.2, 1H, ArH), 5.80 (d, J = 3.9, 1H, H-1′), 5.23 (brs, 1H, H-3′),
5.01 (t, 1H, 5′-OH), 4.20 (m, 1H, H-4′), 3.51 (m, 2H, H-5′, H-5”), 2.55 (d, J = 1.2, H-2′,1H), 2.47 (ddd, J1,8
= 19.0, J1,4 = 6.7, J1,2 = 3.0, 1H, H-2”), 1.76 (d, J = 1.1, 3H, CH3). Spectroscopic data in agreement with
literature [32].
Synthesis of 1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-
dione (13). MF: C10H14N2O5; MW: 242. 3′-anhydrothymidine (12) (0.200 g; 0.892 mmol) in aq. 1.5 M
NaOH (3.33 mL) was stirred in methanol (30 mL) under reflux for 3 h. Upon heating, the solution
changed colour from clear to golden-brown. The reaction was monitored by TLC chromatography.
When the conversion into the final product was confirmed, the solvent was evaporated under
reduced pressure. The resulting crude compound was purified by silica gel column chromatography
(CH2Cl2/CH3OH gradient from 100% to 90% of CH2Cl2) to obtain the final product (13) as a white
powder. Yield: 64%. Rf: 0.4 in 90% CH2Cl2/10% CH3OH TLC system. 1H NMR (500 MHz, DMSO-d6):
δ 11.24 (s, 1H, NH), 7.78 (s, 1H, H-6), 6.07 (dd, J = 8.5, 2.44, 1H, H-1′), 5.25 (d, J = 3.35, 1H, 3′-OH), 4.67
(t, J = 5.49, 1H, 5′-OH), 4.23 (m, 1H, H-3′), 3.60–3.84 (m, 3H, H-4′, H-5′ and H-5”), 2.55–2.59 (m, 1H,
H-2”), 1.84 (dd, J = 14.95, J = 2.14, 1H, H-2′), 1.76 (s, 3H, CH3). Spectroscopic data in agreement with
literature [32].
Synthesis of ((2S)-ethyl-2-(((((2R,3R,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (14). MF: C21H28N3O9P; MW: 497.4.
Compound 14 was synthesised according to standard procedure [16]. 1-(2-deoxy-β-lyxofuranoxyl
thymidine) (13) (1 eq; 0.175 g; 0.721 mmol) was reacted with NMI (5 eq; 0.287 mL; 0.297 g, 3.62 mmol)
and ethyl-(2-chloro(phenyl)phosphorylamino)propanoate (10) (3 eq; 0.633 g; 2.17 mmol) to obtain a
crude residue that was purified by silica gel column chromatography (97% CH2Cl2/3% CH3OH) to
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afford the final compound 14 as a white solid. Yield: 18.4%. Rf: 0.4. 1H NMR (500 MHz, CDCl3): δ
7.58 (d, J = 7.0, 1H, H-6), 7.35–7.43 (m, 2H, Ar-H), 7.20–7.29 (m, 3H, Ar-H), 6.25–6.32 (m, 1H, H-1′), 5.22
(m, 1H, 3′-OH), 4.94 (m, 1H, H-3′), 4.31–4.52 (m, 2H, NH, H-4′), 3.95–4.03 (m, 1H, CH), 3.68 (d, J = 7.0,
2H, CH2-ester), 3.35 (d, J = 16.0, 2H, H-5′, H-5”), 2.48–2.51 (m, 1H, H-2”), 2.09–2.25 (m, 1H, H-2′), 1.85
(d, J = 10.1, 3H, CH3-thy), 1.23 (m, 3H, CH3-ala), 1.16 (d, J = 7.2, 3H, CH3-ester). 31P NMR (200 MHz,
CDCl3): δ 5.34, 4.98.
Synthesis of (2S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-((methylsulfonyl)
oxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (4). MF: C22H30N3O11PS; MW:
575.5. Triethylamine (10 eq; 1.06 mL; 0.769 g; 7.6 mmol) and mesyl chloride (4 eq; 0.235 mL; 0.348
g; 3.04 mmol) were reacted with a solution of compound 14 (1 eq; 0.378 g; 0.76 mmol) in anhydrous
CH2Cl2 (20 mL) at 0 ◦C. The reaction mixture was stirred at 0 ◦C for 10 min and then warmed to rt and
stirred for 1.5 h. The crude mixture was diluted with sat. NaHCO3 solution and extracted with CH2Cl2.
After drying over Na2SO4, the solution was reduced under reduced pressure and the resulting crude
compound was purified by silica gel column chromatography (CH2Cl2/CH3OH gradient from 100%
CH2Cl2 to 95% CH2Cl2) to give the product 4 as a white solid. Yield: 29.5%. Rf: 0.45 in 90% CH2Cl2/10%
CH3OH TLC system. 1H NMR (500 MHz, CDCl3): δ 8.93–8.96 (s, 1H, NH, thy), 7.33–7.32 (d, J = 7.0,
1H, H-6), 7.24–7.28 (m, 2H, Ar-H), 7.10–7.15 (m, 3H, Ar-H), 6.23–6.21 (m, 2H, H-1′), 5.19–5.15 (s, 1H,
NH-ala), 3.84–4.37 (m, 7H, H-3′, H-4′, CH, H-5′, H-5”, CH2-ethyl), 2.96–3.01 (s, 3H, SO2CH3), 2.72–2.75
(m, 1H, H-2”), 2.38–2.42 (m, 1H, H-2′), 1.87 (d, J = 1.2, 3H, CH3-thy), 1.28–1.33 (m, 3H, CH3-ala),
1.19–1.16 (m, 3H, CH3-ethyl). 13C NMR (125 MHz, CDCl3) δ 173.7–173.4 (C=O, acetyl), 163.6 (C-2),
150.42 (C-1), 135.1 (C-4), 129.8 (C-2; C-6Ar), 125.2 (C-4Ar), 120.2 (C-3; C-5Ar), 111.6 (C-3), 83.5 (C-1′),
79.9 (C-3′), 77.3 (C-4′), 63.7 (C-5′), 61.7 (CH2-ethyl), 50.8 (CH-ala), 39.2 (C-2′), 38.8 (CH3-mesyl), 21.34
(CH3-ethyl), 14.04 (CH3-ala), 12.76 (CH3-thy). 31P NMR (202 MHz, CDCl3): δ 2.92, 2.63. MS(ESI+):
576.2 [M + H+]. HPLC: Rt: 13.2 min; Purity > 98%; [Gradient: (0′) 95% H2O/5% CH3CN − (5′) 50%
H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN].
Synthesis of (2S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-(tosyloxy)
tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (5). MF: C28H34N3O11PS; MW: 651.6.
To a solution of compound 14 (1 eq; 0.181 g; 0.364 mmol) in pyridine (5 mL), tosyl chloride (2 eq; 0.138
g; 0.727 mmol) and silver trifluoromethanesulfonate (AgOTf) (2 eq; 0.186 g; 0.727 mmol) were added at
0 ◦C. The reaction was stirred for 1 h and then slowly allowed to warm to rt and stirred for another
2 h. The reaction mixture was then diluted with EtOAc, filtered, and the filtrate was washed with
H2O and brine. The organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated
under reduced pressure. The crude residue was purified by silica gel column chromatography (95%
CH2Cl2/5% CH3OH) to furnish the tosylated compound 5 as a yellowish solid. Yield: 35%. Rf: 0.55.
1H NMR (500 MHz, CDCl3) δ 7.76–7.75 (d, J = 1.9, 1H, H6 Ar), 7.34 (dd, J = 15.7, 8.6, 4H, Ar-H tosyl),
7.27–7.17 (m, 5H, Ar), 6.19–5.20 (td, J = 7.8, 2.9, 1H, H-1′), 4.45–3.74 (m, 10H), 2.72–2.61 (m, 1H, CH-ala),
2.46 (s, 3H, CH3, tosyl), 1.85 (s, 3H, CH3, thy), 1.39 (t, J = 7.2 Hz, 3H, CH3, ethyl), 1.31 (m, 3H, CH3-ala).
13C NMR (126 MHz, CDCl3) δ 173.65, 173.59 (C-ala), 163.52 (C1-thy), 150.58, 150.53 (C3-thy), 150.25,
150.19 (C1-tosyl), 145.99, 145.98 (C1-phenyl), 135.04, 134.95 (CH-thy), 133.05, 132.90 (C4-tosyl), 130.27,
130.21 (CH, C2, C6-tosyl), 129.75, 129.70 (CH, C2, C6-phenyl), 127.64, 127.58 (CH, C4-phenyl), 125.10,
120.35 (CH, C3, C5-phenyl), 120.31, 120.21 (CH, C3, C5-tosyl), 111.15, 110.98 (C3-thy), 84.22, 83.99
(CH, C1′), 80.96, 80.90 (CH, C3′), 80.72, 80.66 (CH, C4′), 63.89, 63.85 (CH2, C5′), 63.33, 63.29 (CH2,
ethyl), 50.39, 50.38 (CH, ala), 39.03 (CH2, C3′), 21.69, 21.00 (CH3-ethyl), 20.96, 20.95 (CH3-tosyl), 14.12
(CH3, ala), 12.49, 12.44 (CH3-thy). 31P NMR (202 MHz, CDCl3) δ 2.78, 2.66. MS (ESI)+: 652.2 [M + H+];
674.1 [M + Na+]. HPLC: Rt: 16.03 min; Purity > 98%; [Gradient: (0′) 95% H2O/5% CH3CN − (5′) 50%
H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN].
Synthesis of (S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-(((4-nitrophenyl)
sulfonyl)oxy)tetrahydrofuran-2yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (6). MF: C27H31N4O13PS;
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MW: 682.5. The ProTide 14 (1 eq; 1.16 g; 2.34 mmol) was dissolved in pyridine (20 mL)
at 0 ◦C. 4-nitrobenzenesulfonylchloride (nosyl chloride) (2 eq; 1.06 g; 4.79 mmol) and silver
trifluoromethanesulfonate (AgOTf) (2 eq; 1.23 g; 4.79 mmol) were added and the reaction mixture was
stirred at 0 ◦C. After 1h the reaction mixture was allowed to slowly warm to rt and stirred for another
2 h. The reaction mixture was then diluted with EtOAc, filtered, and the filtrate was washed with
H2O and brine. The organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated
under reduced pressure. Purification of the crude residue was accomplished by silica gel column
chromatography (95% CH2Cl2/5% CH3OH) to give the desired compound 6 as a yellowish solid. Yield:
60%. Rf: 0.6. 1H NMR (500 MHz, CDCl3) δ 8.77–8.67 (s, 1H, NH, thy), 8.41–8.39 (d, J = 2.2, 2H-Ar,
nosyl), 8.14–8.08 (m, 2H-Ar, nosyl), 7.71 (ddd, J = 7.6, 4.7, 1.7, 1H, H6), 7.42–7.30 (m, 5H-Ar), 6.28–5.28
(m, 1H-H-1′), 4.51–3.75 (m, 7H), 2.79–2.46 (m, 1H, CH-ala), 1.96–1.86 (m, 2H, H-2′, H-2′’), 1.37 (t, J =
7.6, 3H, CH3 ester), 1.31–1.25 (m, 6H, CH3-thy, CH3-ala). 13C NMR (126 MHz, CDCl3) δ 173.66, 173.36
(C-ala), 163.48 (C2, thy), 151.13, 151.10 (C1, thy), 150.29, 150.25 (C1, nosyl), 141.45, 141.35 (C1, phenyl),
134.73, 134.67 (CH, thy), 129.86, 129.81 (CH, C2-6, nosyl), 129.15, 129.13 (CH, C2, C6, phenyl), 125.28
(CH, C4, phenyl), 124.84, 124.77 (CH, C3, C5, phenyl), 120.15, 120.11 (CH, C3, C5, nosyl), 120.06, 120.02,
111.36, 111.23 (C, C3, thy), 84.14, 84.00 (CH, C1′), 80.58, 80.52 (CH, C3′), 80.25, 80.18 (CH, C4′), 63.17,
63.14 (CH2, C5′), 62.82, 62.79 (CH2, ethyl), 50.41, 50.20 (CH, ala), 39.18, 39.16 (CH2, C2′), 20.94, 20.90
(CH3, ethyl), 14.12, 14.11 (CH3, ala), 12.58, 12.56 (CH3, thy). 31P NMR (202 MHz, CDCl3) δ 2.75, 2.48.
MS (ESI)+: 705.1 [M + Na+]. HPLC: Rt: 15.88 min; Purity > 99%; [Gradient: (0′) 95% H2O/5% CH3CN
− (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN].
Synthesis of tert-butyl-3-((2R,4R,5R)-5-(((((tert-butoxycarbonyl)((S)-1-ethoxy-1-oxopropan-2-yl)amino)(phenoxy)
phosphoryl)oxy)methyl)-4-(((4-nitrophenyl)sulfonyl)oxy)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-3,6-
dihydropyrimidine-1(2H)-carboxylate (7). MF: C37H47N4O17PS. MW: 882.83. The nosylated ProTide (6)
(1 eq, 0.050 g, 0.073 mmol) was dissolved in pyridine (6 mL) at rt under nitrogen atmosphere. To the
stirring solution, di(tert-butyl)dicarbonate (Boc2O) (1.3 eq, 0.021 mL, 0.020 g, 0.095 mmol) was added
dropwise and the reaction was stirred for 16h. The crude mixture was evaporated under reduced
pressure and was purified by silica gel column chromatography (CH2Cl2/CH3OH gradient from 100%
CH2Cl2 to 95% CH2Cl2) to give the final di-protected nosylated derivate 7 as a yellowish oil. Yield:
56%. Rf: 0.67 in 90% CH2Cl2/10% CH3OH as TLC system. 1H NMR (500 MHz, CDCl3) δ 8.47–8.36 (d,
2H, J = 2.2, Ar, nosyl), 8.17–8.08 (m, 2H, Ar, nosyl), 7.38 (m, 1H, Ar), 7.32–7.24 (m, 4H), 7.17 (s, 1H, thy),
6.31–6.24 (m, 1H-H-1′), 4.51–3.75 (m, 7H), 2.78–2.43 (m, 1H, CH-Ala), 2.31–2.23 (m, 1H-H-2′), 2.01 (m,
3H, CH3, thy), 1.53–1.49 (m, 9H, CH3, tert-butyl), 1.44 (m, 9H, CH3, tert-butyl), 1.38 (t, J = 7.6, 3H,
CH3, ester), 1.31 (m, 3H, CH3, ala). 13C NMR (126 MHz, CDCl3) δ 175.50, 174.29 (C, ala), 161.32 (C2,
thy), 150.13, 150.08 (C1, thy), 150.02, 150.00 (C1, nosyl) 143.51, 142.21 (C1, phenyl), 132.71, 132.23 (CH,
thy), 130.68, 129.99 (CH, C2–C6, nosyl), 129.34, 129.5 (CH, C2, C6, phenyl), 126.28 (CH, C4, phenyl),
125.79, 124.85 (CH, C3, C5, phenyl), 120.15, 120.13 (CH, C3,C5, nosyl), 120.06, 120.02, 111.36, 111.23 (C,
C3, thy), 84.13, 84.10 (CH, C1′), 80.78–80.77 (C-tert-butyl), 80.58, 80.52 (CH, C3′), 80.25, 80.18 (CH,
C4′), 63.21, 63.20 (CH2, C5′), 62.79, 62.77 (CH2, ethyl), 50.39, 50.30 (CH, ala), 39.18, 39.15 (CH2, C2′),
28.41–28.23 (CH3, tert-butyl), 20.94, 20.90 (CH3, ethyl), 14.12, 14.11 (CH3, ala), 12.58, 12.56 (CH3, thy).
31P NMR: (202 MHz, CDCl3): δ 2.61, 2.53. MS (ESI+): 905.83 [M + Na+]. HPLC: Rt: 17.1 min; Purity >
99%; [Gradient: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN
− (20′) 95% H2O/5% CH3CN].
Synthesis of tert-butyl-3-((2R,4S,5R)-5-((((N-((S)-1-ethoxy-1-oxopropan-2-yl)-3,3-dimethylbutanamido)(phenoxy)
phosphoryl)oxy)methyl)-4-[18F]fluoro-tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-
carboxylate (15). MF: C32H4518FN3O11P; MW: 696.70. Aqueous [18F]fluoride (2–8 GBq) produced by the
cyclotron was trapped in a QMA cartridge and was then eluted through the cartridge by an aqueous
solution of KHCO3 and Kryptofix in CH3CN. The resulting [18F]F-/KHCO3/Kryptofix complex was
dried by an azeotropic distillation with anhydrous CH3CN (2 × 1 mL) under reduced pressure and a
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stream of nitrogen. A solution of the precursor 7 (10 mg) in anhydrous CH3CN (1 mL) was added
and the reaction was stirred for 30 min at 95 ◦C. The resulting reaction mixture was passed through
an alumina cartridge to obtain the radiolabelled product 15. The reaction mixture was analysed by
analytical radio HPLC: Rt: 15 min (analytical HPLC: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50%
CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN).
Synthesis of ethyl ((((2R,3S,5R)-3-[18F]fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-
2-yl)methoxy)(phenoxy)phosphoryl)-l-alaninate (1). MF: C21H2718FN3O8P; MW: 498.43. To the Boc
protected [18F]-radiolabelled ProTide (15), a solution of 2 N HCl (1 mL) was added and the reaction
was stirred for 10 min. The solution was then neutralised with 2 N NaOH (1 mL). The crude mixture
was then purified by semi-preparative HPLC and the desired compound was eluted after 35 min at
a flow rate of 3.5 mL/min using 70% H2O/30% CH3CN as mobile phase. The compound was then
dried under a stream of nitrogen, taken up in saline and flushed through a sterility filter to obtain
the aqueous solution of [18F]FLT ProTide (1). RCY of 15–30% (n = 5, decay-corrected from end of
bombardment (EoB)), with high radiochemical purities (97%) and molar activities of 56 GBq/µmol.
The total synthesis time was 130 min after the end of bombardment (EoB). The reaction mixture was
analyzed by analytical radio-HPLC. Analytical HPLC: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50%
CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN); Rt: 9.5 min.
3.4. Procedures and Analytical Data for the Synthesis of the [18F]FIAU ProTide
Synthesis of 2′-deoxy-2′-α-fluoro-5-iodouridine (19). MW: 372.1; MF: C9H10FIN2O4. Iodine (1.2 eq; 1.24 g;
4.87 mmol) and ceric ammonium nitrate (CAN) (1 eq; 2.23 g; 4.062 mmol) were added to a stirring
solution of 2′-β-fluoro-2′-deoxyuridine (18) (2 eq; 2.0 g; 8.12 mmol) in anhydrous acetonitrile (50 mL).
The mixture was stirred at 75 ◦C for 1 h and was then quenched with a saturated solution of Na2S2O3
and concentrated under reduced pressure. The residue was then re-dissolved in ethyl acetate and
washed twice with saturated NaCl. The organic layer was dried over MgSO4, filtered and concentrated
to give compound 19 as a pale yellow solid. Yield: 60%. HPLC: Rt: 2.3 min; Purity > 95% (98% H2O/2%
CH3CN). 1H NMR (500 MHz, DMSO-d6): δ 11.69 (s, 1H, NH), 8.53 (s, 1H, 6-CH), 5.86 (d, J = 15.8, 1H,
1’-CH), 5.60 (d, J = 6.4, 1H, 3’-OH), 5.39 (t, J = 4.5, 1H, 3’-CH), 5.04 (dd, J = 5.2, 4.1, 1H, 2’-CH), 4.18
(ddd, J = 23.4, 11.4, 7.2, 1H, 4’-CH), 3.90 (d, J = 8.2, 1H, 5’-OH), 3.85–3.79 (m, 1H, 5’-CH), 3.63–3.58 (m,
1H, 5’-CH). 13C NMR (125 MHz, DMSO-d6): δ 167.88 (C=O), 165.01 (C=O), 145.02 (C-6), 125.19 (CH,
C-2’), 121.26 (CH, C-1’), 115.81 (CH, C-4’), 61.11 (CH, C-5), 57.30 (CH, C-3’), 45.87 (CH, C-5’). 19F NMR
(470 MHz, DMSO-d6): δ −202.09. Spectroscopic data in agreement with literature [10].
Synthesis of benzyl(chloro(phenoxy)phosphoryl)-L-alaninate (20). MW: 353.73; MF: C16H17ClNO4P.
Compound 20 was synthesised according to the standard procedure [16]. Anhydrous triethylamine
(2 eq; 1.26 mL; 0.918 g; 9.08 mmol), phenyl dichlorophosphate (1 eq; 0.678 mL; 0.958 g; 4.54 mmol) and
L-alanine benzyl ester hydrochloride salt (1 eq; 1.50 g; 4.54 mmol) were reacted to give compound 20
as a yellowish oil. Yield: 88%. 1H NMR (500 MHz, CDCl3): δ 7.54–7.47 (m, 7H, Ar-H), 7.46–7.40 (m,
3H, Ar-H), 5.27 (d, J = 8.4, 2H, CH2-ester), 4.69 (d, J = 9.9, 1H, NH), 4.13 (dd, J = 34.4, 29.8, 1H, CH-ala),
1.52 (m, 3H, CH3-ala). 31P NMR (202 MHz, CDCl3): δ 8.03, 7.75. Spectroscopic data in agreement with
literature [29–31].
Synthesis of benzyl((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-l-alaninate (21). MF: C25H26FIN3O9P; MW: 689.3.
Compound 21 was prepared according to the standard procedure [16]. 1-(3-Fluoro-4-hydroxy-5-
(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione (19) (1 eq; 0.400 g; 1.07
mmol) and NMI (5 eq; 0.424 mL; 0.439 g; 5.35 mmol) were reacted with benzyl 2-(chloro(phenoxy)
phosphorylamino)propanoate (3 eq; 1.05 g; 3.22 mmol) (20). The crude mixture was purified by silica
gel column chromatography (CH2Cl2/CH3OH from 100% CH2Cl2 to 95% CH2Cl2) to obtain the product
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21 as a yellowish oil. Yield: 10%. 1H NMR (500 MHz, CDCl3): δ 10.59 (s, 1H, 3-NH), 7.89 (s, 1H, 6-CH),
7.53–7.48 (m, 2H, CH-phenyl), 7.45 (t, J = 8.0, 2H, CH-phenyl), 7.41–7.38 (m, 2H, CH-benz), 7.17–7.15
(m, 2H, CH-benz), 7.13 (t, J = 8.0, 1H, CH-benzyl), 7.12 (t, J = 7.4, 1H, CH-phenyl), 5.99 (m, 1H, 1’-CH),
5.79 (dd, J = 47.6, 4.6, 1H, 2’-CH), 5.14 (m, 2H, CH2-benz), 4.90 (m, 2H, 5’-CH2), 4.39 (m, 1H, 4’-CH),
4.27 (m, 1H, 3’-CH), 4.19 (m, 1H, 3’-OH), 4.02 (m, 1H, NH-ala), 3.99 (m, 1H, CH-ala), 1.29 (d, J = 7.0,
3H, CH3-ala). 13C NMR (125 MHz, CDCl3): δ 171.9 (C=O, ala), 168.12 (C=O, C-4), 144.18 (C=O, C-2),
149.0 (C-phenyl), 147.91 (C-benzyl), 145.5, 145.1 (CH, C-6), 128.31–121.48 (CH, Ar-C), 94.3 (C-5), 92.10
(CH, C-4’), 89.13 (CH, C-2’), 83.6, 82.97 (CH, C-1’), 81.08, 80.97 (CH2, C-ester), 69.61, 68.14 (CH, C-3’),
67.23 (CH, C-5’), 52.8 (CH-ala), 21.98 (CH3-ala). 19F NMR (470 MHz, CDCl3): δ -200.91, -201.15. 31P
NMR (202 MHz, CDCl3): δ 3.90, 3.86. MS (ESI)+: 690.3 [M + H+]. HPLC: Rt: 13.4 min; purity > 97%;
[Gradient: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN −
(20′) 95% H2O/5% CH3CN].
Synthesis of (2R,3S,4R,5R)-5-((benzoyloxy)methyl)-3-[18F]fluoro-tetrahydrofuran-2,4-diyl-dibenzoate (17).
MF: C26H2118FO7 MW: 463.4 Aqueous [18F]fluoride (4.11 GBq), produced by the cyclotron was trapped
in a QMA cartridge before it was eluted with an aqueous solution of KHCO3 and Kryptofix in anhydrous
CH3CN. The [18F]F-/KHCO3/Kryptofix complex was dried by co-evaporation with anhydrous CH3CN
(2 × 1 mL) under reduced pressure and a stream of nitrogen. A solution of the triflate precursor (16)
(10 mg) in anhydrous CH3CN (1 mL) was added to the reaction vial and the reaction was stirred for
30 min at 95 ◦C. The mixture was passed through an alumina cartridge to obtain the radiolabelled
product 17 that was used for next step without further purification. The reaction mixture was analysed
by analytical HPLC. Rt: 8.3 min (100% H2O).
Synthesis of 5-iodo-2,4-bis((trimethylsilyl)oxy)pyrimidine (23). MF: C10H19IN2O2Si2; MW: 382.3. To a
solution of 5-iodouracil (22) (1 eq; 10 mg; 0.042 mmol) in dichloroethane (500 µL), hexamethyldisilazane
(11.4 eq; 100 µL; 0.0774 mg; 0.479 mmol) and TMSOTf (13.1 eq; 100 µL, 0.123 mg; 0.549 mmol) were
added. The mixture was stirred for 2 h at 85 ◦C and was used for next step without further purification.
The purity of the compound was assessed by analytical HPLC (Rt = 6.9 min; 88% H2O/12% CH3CN)
and LC-MS ([M + H+]: 383.2). Spectroscopic data was in agreement with literature [10].
Synthesis of 1-((2R,3S,4R,5R)-3-[18F]fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-
2,4(1H,3H)-dione ([18F]FIAU) (24). MF: C9H1018FN2O5 MW: 371.0. Compound 17 was delivered to a vial
containing 2-4-bis(trimethylsilyl)-5-iodouracil (23). The mixture was then heated at 85 ◦C for 60 min.
To this mixture, 0.5 M of NaOCH3 in CH3OH (1 mL) was then added and the reaction was stirred
at 85 ◦C for another 5 min. The precipitate was then reconstituted in water (1 mL) and neutralised
with 6 N HCl. The reaction mixture was analyzed by analytical HPLC showing the formation of the 2
anomers (α and β) of the 2′-deoxy-2′-fluoro-5-iodouridine. Analytical HPLC: 98% H2O/2% CH3CN;
Rt: α anomer 2.1 min; β anomer 2.9 min). The anomeric mixture was then purified by semi-preparative
HPLC and the target compound (24) was eluted after 7.3 min at a flow rate of 3.5 mL/min using 20%
CH3CN/80% H2O as mobile phase to obtain the final compound. HPLC: Rt: 2.1 min; 98% H2O/2%
CH3CN. Data in agreement with literature [10].
Synthesis of [18F]FIAU ProTide (2). MF: C25H2618FIN3O9P; MW: 688.3. To [18F]FIAU (24), NMI (0.1 mL)
and a solution of benzyl-2-(chloro(benzyloxy)phosphorylamino)propanoate (20) (0.050 g) in anhydrous
THF (0.5 mL) were added together under nitrogen atmosphere. The reaction mixture was stirred
at 50 ◦C for 20 min and then dried under a flow of nitrogen, re-dissolved in CH3CN and purified
via semi-preparative HPLC. The compound 2 was eluted after 23 min at a flow rate of 3.5 mL/min
using 50% CH3CN/50% H2O as the mobile phase. The solvent was then removed from the mixture
under a stream of nitrogen. The final product was then re-formulated in saline and flushed through
a sterility filter to furnish a clean sterile aqueous solution of [18F]FIAU ProTide (2). Radiochemical
reactions were carried out using starting activities between 4–15 GBq, leading to RCY’s of 1–5% (n = 7,
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decay-corrected from end of bombardment (EoB)), with high radiochemical purities (98%) and molar
activities of 53 GBq/µmol. The total synthesis time was 240 min after the end of bombardment (EoB).
Analytical HPLC: (0′) 95% H2O/5% CH3CN - (5′) 50% H2O/50% CH3CN- (15′) 50% H2O/50% CH3CN-
(20′) 95% H2O/5% CH3CN); Rt: 12.3 min.
4. Conclusions
Phosphoramidate ProTide technology is a successful prodrug strategy to deliver nucleosides
to their target sites, reducing toxicity issues and improving the potency of their parent nucleosides.
Several fluorinated ProTides are currently being evaluated as anticancer and antiviral agents at different
stages of clinical trials. PET imaging has the potential to provide the pharmacokinetic profile of certain
drug candidates directly in vivo and therefore to predict the response to therapy. In this study we have
developed the first radiochemical synthesis of the [18F]FLT ProTide (1) chosen as a model standard
of the class of 3′-fluorinated ProTides. An automated late stage [18F]fluorination was tested on four
different precursors with the best yields obtained when using a di-Boc protected nosyl derivative (7).
The late stage fluorination and easy purification make this tracer a good candidate as a PET imaging
probe with substantial potential for clinical application.
[18F]FIAU ProTide (2) was synthesised as a model of the class of 2-‘fluorinated ProTides. Despite
the early stage introduction of the fluorine-18, we have optimized the following steps involving the
formation of the phosphoramidate bond. This optimization reduced the overall reaction time whilst
maintaining a reasonable yield and high purity of the final compound.
To our knowledge, this is the first time that [18F] radiolabelled ProTides have been synthesised.
These radiotracers have the potential in preclinical models to further elucidate the in vivo mechanism
of biodistribution and metabolism, as well as to be clinically translated for diagnostic and therapeutic
evaluation purposes.
Supplementary Materials: The following are available online. Figure S1. Internalization and metabolism of
ProTides, bypassing the first-rate limiting step of the nucleoside analogues phosphorylation cascade; Figure S2. 31P
NMR stability study; Figure S3: E&Z modular lab sketch; Figure S4: Representative analytical HPLC chromatogram
for the fluorination of the mesyl precursor 4; Figure S5: Representative analytical HPLC chromatogram for the
fluorination of the tosyl precursor 5; Figure S6: Representative analytical HPLC chromatogram for the fluorination
of the nosyl unprotected precursor 6; Figure S7: Representative analytical HPLC chromatogram of the fluorination
of the nosyl protected precursor 7; Figure S8: Representative analytical HPLC chromatogram for the deprotection of
the precursor 15 before purification; Figure S9: Representative analytical HPLC chromatogram for the fluorination
of the sugar; Figure S10: Representative analytical HPLC chromatogram of the glycosylation reaction; Figure S11:
Representative analytical HPLC chromatogram of the coupling reaction; Table S1: Radiolabelling attempts for the
mesyl precursor (compound 4); Table S2: Radiolabelling attempts for the tosyl precursor (compound 5); Table S3:
Radiolabelling attempts for the unprotected nosyl precursor (compound 6).
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